Focus: BioMarin is a $2.4B revenue public specialty pharma company focused on rare disease biologics, particularly in lysosomal storage disorders, metabolic disorders, and genetic conditions. They operate at significant scale with a diversified portfolio of FDA-approved enzyme replacement therapies and small molecule treatments.
Profile data last refreshed 16h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow BioMarin Pharmaceutical to get notified when they start hiring — the background below is worth knowing for when they do.
Flagship revenue driver at 35% of company revenue; only pegvaliase PAL enzyme approved for PKU, representing novel mechanism competing with traditional cofactor therapy.
Help build intelligence for BioMarin Pharmaceutical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from BioMarin Pharmaceutical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Second-largest revenue contributor; enzyme replacement therapy for rare lysosomal storage disorder with stable reimbursement and patient base.
Cofactor therapy for PKU with extended exclusivity; Phase 3 studies ongoing for expanded indications in PKU population.
First-in-class therapy for achondroplasia with longest patent tail (2042); represents expansion into growth disorder market with significant unmet need.
Gene-adjacent CNS therapy for rare pediatric neurodegenerative disease; demonstrates company's expansion into CNS and ultra-rare indications.
Legacy enzyme replacement therapy approaching loss of exclusivity; revenue expected to erode as biosimilar competition intensifies.
Aging MPS VI therapy approaching exclusivity loss; lower revenue base reflects mature lifecycle and emerging competitive therapies.
Precision Trading with Biomarin Pharmaceutical Inc. (BMRN) Risk Zones - Stock Traders Daily
Precision Trading with Biomarin Pharmaceutical Inc. (BMRN) Risk Zones Stock Traders Daily
BioMarin Amicus Deal Expands Rare Disease Reach And Adds Kidney Asset - simplywall.st
BioMarin Amicus Deal Expands Rare Disease Reach And Adds Kidney Asset simplywall.st
BioMarin acquires Amicus Therapeutics for $4.8bn - Pharmaceutical Technology
BioMarin acquires Amicus Therapeutics for $4.8bn Pharmaceutical Technology
Why BioMarin Pharmaceutical Stock Topped the Market on Tuesday - MSN
Why BioMarin Pharmaceutical Stock Topped the Market on Tuesday MSN
BioMarin Pharmaceutical Closes $4.8 Billion Acquisition of Amicus Therapeutics - marketscreener.com
BioMarin Pharmaceutical Closes $4.8 Billion Acquisition of Amicus Therapeutics marketscreener.com
BioMarin (NASDAQ: BMRN) adds Galafold and Pombiliti in Amicus deal - Stock Titan
BioMarin (NASDAQ: BMRN) adds Galafold and Pombiliti in Amicus deal Stock Titan
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
No material regulatory warnings, product shortages, or recent restructuring signals suggest operational stability; however, zero public hiring signals warrant direct reference checks on actual hiring pace.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo